Pharmacyclics inks manufacturing deal

Article

MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and

MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and pelvis. The agent last month completedphase-three clinical trials and Pharmacyclics plans to submita new drug application in the middle of this year.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.